Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

BACKGROUND: To compare the clinical efficacy of New York Esophageal squamous cell carcinoma-1 (NY-ESO-1) vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in a randomized, double-blind phase II study in participants with fully resected melanoma at high risk of recurrence. METHODS: Participant...

Descripción completa

Detalles Bibliográficos
Autores principales: Cebon, Jonathan S, Gore, Martin, Thompson, John F, Davis, Ian D, McArthur, Grant A, Walpole, Euan, Smithers, Mark, Cerundolo, Vincenzo, Dunbar, P Rod, MacGregor, Duncan, Fisher, Cyril, Millward, Michael, Nathan, Paul, Findlay, Michael P N, Hersey, Peter, Evans, T R Jeffry, Ottensmeier, Christian Hermann, Marsden, Jeremy, Dalgleish, Angus G, Corrie, Pippa G, Maria, Marples, Brimble, Margaret, Williams, Geoff, Winkler, Sintia, Jackson, Heather M, Endo-Munoz, Liliana, Tutuka, Candani S A, Venhaus, Ralph, Old, Lloyd J, Haack, Dennis, Maraskovsky, Eugene, Behren, Andreas, Chen, Weisan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204806/
https://www.ncbi.nlm.nih.gov/pubmed/32317292
http://dx.doi.org/10.1136/jitc-2019-000410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204806/
https://www.ncbi.nlm.nih.gov/pubmed/32317292
http://dx.doi.org/10.1136/jitc-2019-000410

Ejemplares similares